Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock between February 21 and February 24, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Songjiang Ma, the President of Gyre Therapeutics, sold shares of the company's common stock.
• The sales occurred on February 21 and February 24, 2025.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• On February 21, 2025, 1,818 shares were sold at a weighted average price of $11.84, and 182 shares were sold at a weighted average price of $12.6.
• On February 24, 2025, 1,813 shares were sold at a weighted average price of $10.6, and 187 shares were sold at a weighted average price of $11.52.
• Following these transactions, Mr. Ma indirectly owns 2,859,260 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock sales by an insider under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on current market information.

Stakeholder Impact

• Shareholders may be interested in insider trading activity as an indicator of management's confidence in the company.
• The sales could exert downward pressure on the stock price, although the impact is likely to be limited due to the pre-planned nature of the transactions.

Key Dates